Kliman Gilbert H sold $475K of GKOS

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

H.C. Wainwright raised its Glaukos (NYSE:GKOS) price target to $195 from $168 and kept a Buy rating after Glaukos reported Q2 2026 results. Revenue was $185.6M, up 49.5% YoY, and glaucoma revenue was $155.2M. Glaukos raised full-year 2026 net sales guidance to $680M-$700M.